Differential CARM1 expression in prostate and colorectal cancers

Abstract

BackgroundCoactivator-associated arginine methyltransferase 1 (CARM1) functions as a transcriptional coactivator of androgen receptor (AR)-mediated signaling. Correspondingly, overexpression of CARM1 has been associated with the development of prostate cancer (PCa) and its progression to androgen-independent PCa. In our preliminary study, however, the promoting effects of CARM1, with regard to androgen-stimulated AR target gene expression were minimal. These results suggested that the AR target gene expression associated with CARM1 may result primarily from non-hormone dependent activity. The goal of this study was to confirm the pattern of expression of CARM1 in human tumors and determine the mechanism of action in CARM1 overexpressed tumors.MethodsTissue microarray was used to determine the pattern of expression of CARM1 in human cancers by immunohistochemistry. CARM1 expression was also evaluated in prostate and colorectal surgical specimens and the clinical records of all cases were reviewed. In addition, a reporter transcription assay using the prostate-specific antigen (PSA) promoter was used to identify the signaling pathways involved in non-hormone-mediated signal activation associated with CARM1.ResultsThe tissue microarray showed that CARM1 was particularly overexpressed in the colorectal cancers while CARM1 expression was not prevalent in the prostate and breast cancers. Further studies using surgical specimens demonstrated that CARM1 was highly overexpressed in 75% of colorectal cancers (49 out of 65) but not in the androgen-independent PCa. In addition, CARM1's coactivating effect on the entire PSA promoter was very limited in both androgen-dependent and androgen-independent PCa cells. These results suggest that there are other factors associated with CARM1 expression in PSA regulation. Indeed, CARM1 significantly regulated both p53 and NF-κB target gene transcription.ConclusionsThe results of this study suggest that, in addition to its role in activation of steroid receptors, CARM1 functions as a transcriptional modulator by altering the activity of many transcriptional factors, especially with regard to androgen independent PCa and colorectal cancers.

PRMT7 Induces Epithelial-to-Mesenchymal Transition and Promotes Metastasis in Breast Cancer

“…In this study, we focused on an important epigenetic modifier, PRMT7, whose physiologic roles have been established in male imprinted gene methylation, mRNA splicing, DNA repair, and neural cell differentiation (17,(20)(21)(22). To date, PRMT7 has not been studied in association with cancer progression, although other members of the PRMT family, such as PRMT1, PRMT4/CARM1, PRMT5 and PRMT6, have been found to be either upregulated or downregulated in prostate cancer, breast cancer, colon carcinoma, and melanoma (36)(37)(38)(39). Data arising from this study unraveled, for the first time, the functional role of PRMT7 in regulating the EMT in breast cancer.…”

Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells

“…3A and B) and T47D Aberrant expression of PRMTs has been observed in several cancers, including breast, lung, colorectal, bladder and leukemia. [7][8][9][10][11][12][13][14][15] PRMT4/CARM1 expression is elevated in prostate and breast cancer, and it is thought to play a role in the regulation of hormone-dependent proliferation. 8,16 Additionally, PRMT5 expression is upregulated in mantle cell lymphoma and enhances anchorage-independent cell growth.…”

Transition state mimics are valuable mechanistic probes for structural studies with the arginine methyltransferase CARM1

“…Coactivator associated arginine methyltransferase 1 (CARM1, also known as PRMT4) is directly involved in numerous cellular processes via methylation of the histone H3 tail peptide, splicing factors, RNA binding proteins, and coactivation of nuclear receptors (1,5). Growing evidence indicates associations with the up-regulation of CARM1 in breast (6,7), colon (8,9), prostate (9,10), and liver (11) cancers, making it an appealing potential therapeutic target.…”